PT  - JOURNAL ARTICLE
AU  - Hoyle, Brian
TI  - Safety and Efficacy of DTG Plus ABC/3TC for Treatment-Naïve Patients with HIV
DP  - 2014 Dec 01
TA  - MD Conference Express
PG  - 19--21
VI  - 14
IP  - 28
4099  - http://mdc.sagepub.com/content/14/28/19.short
4100  - http://mdc.sagepub.com/content/14/28/19.full
AB  - Results from a 48-week, open-label extension of A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla [SINGLE, NCT01263015], a phase 3, randomized, double-blind trial, have reaffirmed week 48 and week 96 results [Walmsley SL et al. N Engl J Med. 2013] of the superiority of once-daily dolutegravir 50 mg used with abacavir/lamivudine compared with efavirenz/tenofovir/emtricitabine in treatment-naïve patients with HIV-1.